Skip to main content

Schroeder Thilo's Form 4 filing

Revolution Medicines, Inc.RVMD · filed Mar 4, 2022

Accession no.
0001209191-22-016484
Filed
Mar 4, 2022
Trade date
Feb 18, 2020-Mar 4, 2022
Filing delay
745 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market purchases total $28.6M. It was filed 745 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schroeder ThiloCIK 0001776412Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 18, 2020Common StockCConversionAcquired+2,118,214–F1–2,118,214Indirect
Feb 18, 2020Common StockPPurchaseAcquired+400,000$17.00+$6,800,0002,518,214Indirect
Jul 13, 2020Common StockPPurchaseAcquired+150,000$26.00+$3,900,0002,668,214Indirect
Feb 8, 2021Common StockPPurchaseAcquired+300,000$45.00+$13,500,000300,000Indirect
Mar 2, 2022Common StockPPurchaseAcquired+116,290$18.94F4+$2,202,532.6116,290Indirect
Mar 3, 2022Common StockPPurchaseAcquired+54,764$18.42F6+$1,008,752.88171,054Indirect
Mar 3, 2022Common StockPPurchaseAcquired+10,873$19.13F7+$208,000.49181,927Indirect
Mar 4, 2022Common StockPPurchaseAcquired+56,300$17.69F8+$995,947238,227Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 18, 2020Common StockCConversionDisposed−1,569,539–F1–0Indirect
Feb 18, 2020Common StockCConversionDisposed−548,675–F1–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering.

Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.

F4

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.62 to $19.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.03 to $18.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $18.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)